The Experimental Therapeutics (ET) Program is the hub that connects and coordinates discoveries made in the basic sciences with translational research and clinical trials.
The program’s overarching goal is to improve patient outcomes by identifying and validating novel therapeutic targets, fostering translational research, and conducting clinical research to assess the effectiveness of new treatments in humans.
Within those themes, the ET program has two specific aims:
- Develop novel cancer therapies based on discoveries from HCI science.
- Develop innovative treatment interventions and conduct translational and clinical research with emphasis on cancer relevant to the Mountain West.
ET Leadership
Howard Colman, MD, PhD
Co-Leader
View Profile
Martin McMahon, PhD
Co-Leader
View Profile
Program Membership
HCI Cancer Center members enjoy a variety of benefits, including eligibility for leadership roles in the Center, institutional funding opportunities, and scientific/administrative support.